Q Bio

Executive Summary

Q Bio is a preventive health technology company that integrates physics-based imaging, AI analytics, genomics, and wearable data to create a digital twin of an individual’s health. Its flagship 75-minute comprehensive physical exam includes full-body MRI, EKG, genetic testing, and biometrics, followed by AI-driven insights for clinicians and patients. Founded in 2020 and headquartered in San Carlos, California, the company has raised $30 million and operates as a private platform-stage business. By shifting the focus from reactive disease management to proactive wellness, Q Bio aims to enable early detection and personalized intervention, potentially reducing long-term healthcare costs and improving outcomes. The digital twin serves as a continuous, evolving health record that can be updated with new data over time, offering a longitudinal view of an individual's health trajectory. Q Bio addresses the growing demand for precision preventive care, differentiated by its combination of advanced imaging, multi-omic analysis, and AI-powered interpretation. The company targets both direct-to-consumer and employer/health system channels, leveraging its digital twin platform to drive engagement and adherence. However, its success depends on navigating regulatory pathways, demonstrating clinical validity, and scaling operations affordably. With a strong technological foundation and early market traction, Q Bio is well-positioned to capitalize on the shift toward value-based care. The primary risks include reimbursement challenges, competition from emerging digital health platforms, and the need to secure additional capital for commercial expansion. Overall, Q Bio has a promising yet unproven model that requires execution to achieve widespread adoption.

Upcoming Catalysts (preview)

• Q3 2026Series B funding round to support commercial scaling75% success
• Q4 2026Strategic partnership with a major health system or employer group60% success
• Q2 2027Publication of clinical outcomes data from pilot studies80% success